Item 8.01 Other Events.

On January 24, 2020, Liquidia Technologies, Inc. (the "Company") submitted a new drug application, or NDA, to the U.S. Food and Drug Administration for LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension, or PAH. On January 27, 2020, the Company issued a press release announcing the NDA submission. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d)



Exhibit
No.                             Exhibit

  99.1         Press Release of Liquidia Technologies, Inc., dated January 27, 2020.

© Edgar Online, source Glimpses